Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation. Journal of magnetic resonance imaging Kim, H., Hartman, Y. E., Zhai, G., Chung, T. K., Korb, M. L., Beasley, T. M., Zhou, T., Rosenthal, E. L. 2015; 42 (4): 936-945

Abstract

To assess the early therapeutic effects of anti-EMMPRIN (extracellular matrix metalloprotease inducer) antibody with/without cisplatin or X-ray radiation in head and neck cancer mouse models using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).Mice bearing SCC1 (or OSC19) tumor xenografts were treated with anti-EMMPRIN antibody, radiation, cisplatin, or anti-EMMPRIN antibody plus cisplatin (or radiation) for a week (n?=?4-5 per group). DCE-MRI was carried out on a 9.4T small animal MR scanner on days 0, 3, and 7, and K(trans) values were averaged in a 0.5-mm-thick peripheral tumor region. Ki67 and CD31 staining were implemented for all tumors after imaging.The K(trans) changes of SCC1 and OSC19 tumors treated with anti-EMMPRIN antibody for 3 days were -18?±?8% and 4?±?7%, respectively, which were significantly lower than those of control groups (39?±?5% and 45?±?7%; P?=?0.0025 and 0.0220, respectively). When cisplatin was added, those were -42?±?9% and -44?±?9%, respectively, and with radiation, -45?±?9% and -27?±?10%, respectively, which were also significantly lower than those of control groups (P?

View details for DOI 10.1002/jmri.24871

View details for PubMedID 25704985

View details for PubMedCentralID PMC4545484